Figure 6. Tigecycline inhibits B cell lymphoma, in vivo, prolonging survival.
A. and D. Kaplan-Meier survival curves of C57Bl/6 mice injected intravenously with GFP-expressing Eμ-myc lymphoma cells and administered tigecycline (Tig) or PBS (vehicle control) starting the day of injection (A, p < 0.0001, log-rank test) or once the lymphoma had established on day nine indicated by an arrow (D, p < 0.0001, log-rank test). B. and E. For the mice in A and D, respectively, white blood cell counts (WBC) and GFP positive cells (lymphoma) in the blood, as measured by flow cytometry (C and F, respectively), were determined on the days indicated. The number (n) of mice in each group is indicated. B, *P = 4.43×10−6, **P = 1.57×10−5; C, *P = 1.58×10−5; **P = 1.57×10−8; E, *P = 7.23×10−4, **P = 9.42×10−6; F, *P = 4.77×10−7; **P = 4.02×10−9; t-tests.